LAS VEGAS, NEV., (May 20, 2021) — Subchondral Solutions, Inc, a medical device company based in Huntington Beach, Calif., is receiving support for its S-Core platform technology™ from key opinion leaders at this year’s American College of Foot and Ankle Surgeons (ACFAS) conference in Las Vegas. The support for the innovative platform will hasten the commercial launch of the product.
“We are happy to report we’re ready for our full commercial launch,” says Tom Kinder, CEO of Subchondral Solutions. “After meeting with surgeons from 23 different states at the ACFAS, we realized surgeons are prepared to use our platform now for their patients.”
Cleared by the FDA in 2020, the S-Core platform technology™ is indicated for fixation of small bone fragments, such as osteochondral fragments and cancellous fragments, appropriate for the size of the device which may include the following: simple metaphyseal fractures; condylar fractures; osteochondritis dissecans; areas where accurate screw placement is vital; patellar fractures, navicular fractures, cancellous bone fragments; osteochondral fragments, intra-articular fractures and osteochondral fixation and fractures, and minimally invasive reconstruction of fractures and joints. S-Core™ can be used in any osteochondral fracture appropriate for the size of the device, including for the knee, elbow, hand, foot, ankle, shoulder and hip.
“We met with some of the most respected key opinion leaders and they are excited to begin using S-Core™,” said Jordan Peana, director of sales at Subchondral Solutions. “They recognize that our bio-active implants will maximize bone and biologic healing.”
About Subchondral Solutions, Inc.
Subchondral Solutions was formed in 2013 and is committed to advancing the treatment of joint damage by addressing the source of the problem with a biomechanical, efficient, cost-effective scalable system. Contact us at 888-410-5622 or online at subchondralsolutions.com